Company Overview
Biosolvix is the first specialized Organoid CRO (Contract Research Organization) in South Korea
We are providing innovative solutions that can enhance the quality of life (QOL) for both humans and animals through the development of advanced diagnostic technologies and alternative therapies
VISION
Providing innovative solutions to enhance the quality of life (QOL) for both humans and animals through the development of advanced diagnostic technologies and alternative therapies
MISSION
Contributing to the improvement of the quality of life for both humans and animals with a goal of an IPO by 2028.
CORE VALUE
- Innovation – We think differently to enhance the quality of life for both humans and animals.
- Collaboration – We foster a culture of inclusivity with diverse partners and customers to improve quality of life.
- Impact – We contribute to society by advancing the field of human and animal health.
INNOVATION
COLLABORATION
IMPACT
COMPANY PROFILEComprised of bio-specialized management and a team with rich research experience
CORE PLAN
Organoid banking
Drug Screening
Cancer Organoid
Drug Toxicity Study
COMPANY HISTORY
- March 2024 Signed MOU with Dongkook Pharmaceutical
- February 2024 Signed Material Transfer and Research Service Agreement with Company D
- February 2024 Filed a patent for CD34
- January 2024 Signed joint research agreement for colorectal and lung cancer with Samsung Seoul Hospital
- Dec 2023 Signed MOU with Dt&CRO for the Development of Non-clinical and Alternative Testing Fields
- Nov 2023 Signed MOU with Catholic University's Surgery Dep. for the development of Organoid technology
- Nov 2023 Opening of the Biosolvix Research & Development Center
- Nov 2023 Selected for TIPS(Tech Incubator Program for Startup) & Agreement Signing
- Oct 2023 Signed MOU with Samsung Medical Center for Cancer Organoid research
- Oct 2023 Successfully completed Seed funding
- Sep 2023 Awarded the Grand Prize at the IRIS Startup Challenge Demo Day
- Sep 2023 Headquarters Relocation
- Aug 2023 Initiated the beta service for toxicity/efficacy
- Aug 2023 Concluded the AI toxicity technology transfer agreement
- Aug 2023 Executed the SFI Chip(Organ on a chip) transfer agreement
- Aug 2023 Signed a research contract with Chung-Ang University
- Jul 2023 Selected as an operator for the Tech Incubator Program for Startups (TIPS)
- Jul 2023 Participation in InterBiz (16 company meetings)
- Jun 2023 Selected for the 1st IRIS Startup Challenge
- May 2023 Selected as a BioCube by Korea Biotechnology Industry Organization
- May 2023 Corporate establishment and Business registration
WRITE USSend Us a Message and Learn More About Our Services
OUR TEAMWe'll Ensure You Always Get the Best Results
Biosolvix aims to provide drug development efficacy and toxicity measurement technology services that are safe for humans and minimize ethical concerns related to animal testing. By producing multiple human-like organoids to reduce animal testing, we intend to offer cost-effective efficacy and toxicity assessments to various small and medium-sized businesses and venture companies.
CEOChoi Soo Young, PhD
Ph.D. from Seoul National University College of Pharmacy
Doctoral degree from Kyoto University Chemistry Research Institute, Japan B.S., M.S.,
Post-Doctoral research at Harvard Medical School, USA
Doctoral degree from Kyoto University Chemistry Research Institute, Japan B.S., M.S.,
Post-Doctoral research at Harvard Medical School, USA
CMOPark Shin Hoo, MD PhD
Vice President
CTOSoon-Jung Park, PhD
Director of Research
CFOPark Woo Hyun
Management Planning Executive
CSOLee Song Ee, PhD
Director of Strategy Planning Division
Moon Han Rim, MD PhD
Non-executive advisor
© 2023 BioSolvix All rights reserved.